tenofovir has been researched along with sorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anugwom, CM; Bane, A; Braimoh, GA; Debes, JD; Sultan, A; Wondifraw, Z | 1 |
1 review(s) available for tenofovir and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for tenofovir and sorafenib
| Article | Year |
|---|---|
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Doxorubicin; End Stage Liver Disease; Ethiodized Oil; Ethiopia; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Tenofovir; Treatment Outcome | 2020 |